Author – Nairuti Patel (Associate Consultant, GPI) On 3rd March 2020, the Spanish Council of Ministers announced a ‘specific pricing system’ for orphan medicinal product that will be separate from the reference pricing system. The reference pricing system applies to all other products reimbursed by the Spanish National Health System (SNS) when their patent has expired. The only instance when orphan drugs will be included in this new…
At the end of 2019, important legislative changes took place in the United States that could impact the country’s pharmaceutical industry over the coming years. The U.S. House of Representatives has passed the Lower Drug Costs Now Act on 12th December 2019, setting…
By Pramod Kumar Mali, Senior Business Analyst Back in August 2019, GPI reported the new regulations finalized by Canada to tackle high drug prices by making amendments to the Patented Medicines Regulations. On November 21, 2019, the Patented Medicines Prices Review Board (“PMPRB”)…
Global Pricing Innovations will be sponsoring the drinks reception at World Pharma Pricing Market Access and Evidence Congress 2020 on the 18th March 2020 at Amsterdam’s Beurs van Berlage venue. GPI will be officially launching and providing an exclusive sneak peak at our…
By Ines Dieringer – Associate Consultant With new mutations which are driving oncogenesis in life-threatening cancers being discovered everyday, the industry looks be keeping pace with targeted therapies for these mutagenic targets. One such example is Novartis’ investigational therapy Capmatinib. This investigational therapy…
Global Pricing Innovations will be attending the World Pharma Pricing, Market Access & Evidence Congress in Amsterdam on the 18th and 19th March 2020. Please reach out to our Business Development Manager to arrange a meeting at the event. Musa Kureshy – Business…
Pfizer has planned the launch of its biosimilar competitors in the U.S. to Roche’s cancer drugs, Avastin, Herceptin, and Rituxan, at significantly discounted prices, in comparison to the originators. Experts have noted that the launch of these medicines can lead to substantial savings…
London January 22nd, 2020 Today, Global Pricing Innovations (GPI), the pricing experts, are pleased to announce the relocation of its Head Office in London from 31st January 2020 to support GPI’s continued growth and expansion plans. The new facility, based in the heart…
In recent developments, the Pharmaceutical and Healthcare Association of the Philippines (PHAP) offered substantial price reductions (up to 75%) for over 150 medicines in 36 disease categories. Drugs covered by this reduction include several oncology medicines (for breast, lung, ovarian, lymphatic cancers and…
Last week, the result of negotiations between pharma companies and China’s National Healthcare Security administration was revealed. 150 medicines were evaluated, and the outcome is as follows. Out of the 119 new medicines evaluated, 70 were accepted onto the National Reimbursement Drug List…
Preeti Patel, the CEO of GPI, was invited to the Good Growth Summit, an event designed to inspire and connect female entrepreneurs across the US and UK tech ecosystem. The Summit took part at the St James’s Palace and was hosted by Princess…
This week, GPI had the pleasure to be invited to the Silicon Valley Comes to the UK (SVC2UK) summit. SVC2UK is an annual tech conference that brings world-leading tech entrepreneurs and investors to the UK for a series of workshops, panel discussions and…
Every three years the Federal Office of Public Health (FOPH) reviews the reimbursement conditions and, more specifically, the prices of the medicines in the list of specialities covered by the compulsory health insurance (OKP). The medicines are split into three equal groups, containing…
Today Global Pricing Innovations (GPI) reports that it has validated an analytical method for forecasting new drug price potential during early stage development, opening a pathway to digital transformation for teams engaged in pricing and market access. GPI has successfully forecasted prices…
Luxturna (voretigen neparvovec), a gene therapy developed by Novartis, received ‘considerable added benefit’ from G-BA, the German health technology assessment. Luxturna is a one-off treatment for vision loss in adults and children, caused by retinal dystrophy from mutations in both copies of…
BeNeLuxA collaboration is a joint initiative on drug pricing and reimbursement between the governments of Belgium, The Netherlands, Luxembourg, Austria and Ireland, with the aim of giving smaller countries greater negotiating power in discussing drug pricing with international drug firms. The group was…
In April 2019, the Spanish government submitted its ‘Updated Stability Program for 2019-2022’ to the European Union, reiterating the commitment to keep the national healthcare expenditure to 6% of the GDP. New and continuing budget control measures targeting the pharmaceutical expense, which comprise 19%…
Roche announced on Thursday, August 29, that Tecentriq (atezolizumab) in combination with Abraxane (protein-bound paclitaxel) had been approved in Europe for patients with PD-L1-positive, metastatic triple-negative breast cancer (TNBC). The Tecentriq combination marks the first cancer immunotherapy regimen to be available in…
On 1st August 2019, Italy’s State-Regions Conference approved a decree to reform the pharmaceutical pricing system of the country. A press release issued by the Ministry of Health states that the ‘Price Decree’ changes the procedures for the negotiation of the price…
President Trump’s administration has proposed to create an International Pricing Index (IPI) model for Medicare Plan B, which could bring international reference pricing (IRP) to the United States. The proposed change would apply to physician-administered therapies (covered by Medicare Part B) but not…
Earlier this month, the Government of Canada announced the final amendments to the Patented Medicines Regulations which estimates to save Canadians around $13 billion in the next decade and lay the foundation for National Pharmacare. The most significant reform to the regulations since…
Amendments to the Pharmaceutical Law in Russia will take effect from June 2019 and will be completed by 1st January 2021. Medicines which are reimbursed in Russia are listed on the Essential Drugs List (EDL), in which there are currently 735 products,…
Only recently did FDA approve Zolgensma® (by AveXis, a Novartis company), a gene therapy costing 2.1$ million, making it the most expensive medicine in the history of pharma. Zolgensma®’s most compelling feature is that it is a ‘one-off’ treatment. It utilises a…
Learn how GPI’s ground-breaking new approach to early price setting and TPP optimisation can quantify the value of your product, predict payer response and forecast price potential. Obtain unbiased, rapid insights in days, not months, saving you time and resources.
New pharmaceutical pricing rules were approved this past April in Kazakhstan. The new price control measures extended their scope from medicines within the state procurement system to pharmaceutical products sold in private marketing channels, such as in wholesale and pharmacies. In addition,…
Earlier this month, the Malaysian Ministry of Health has approved the introduction of international reference pricing (IRP) to benchmark medicines prices and ‘expand access to expensive new medicines’. A ceiling price will be derived from the average of the three lowest prices…
International Reference Pricing (IRP) is constantly under the spotlight as an effective mechanism to regulate the prices of medical products. In the USA there was a concern to implement IRP in an effort to try and constrain the increased prices of drugs in…
By Alexandros Soumalevris, GPI Working towards Health Technology Assessment (HTA) harmonisation There have been calls for the European Union (EU) countries, the European Parliament and other interested parties initiated in 2016 to the European Commission, to work on strengthening EU cooperation…
Madhuri Chhatbar HR Manager Joined GPI in September 2018 Kicking off our Tuesday with our next employee spotlight – Madhuri Chhatbar. Madhuri is our HR manager out in our Mumbai office and plays a crucial part not only with our employees but…
Pramod Mali Senior Business Analyst Joined GPI in February 2018 Our Employee Spotlight for this week focuses on Pramod Mali. Pramod is one of our superstar Senior Business Analysts in our office in Mumbai. Our HR manager Madhuri managed to catch Pramod…
By Preeti Patel Finding the right price in a cost-constrained global healthcare environment Needless to reiterate that costs of healthcare continue to increase. Some of the main drivers behind this trend are the development costs of novel and efficacious medicines which have the…
Popat Bankar Business Analyst Joined GPI Mumbai in January 2017 Up this week in our Employee Spotlight Series is our Business Analyst – Popat Bankar. Popat is apart of our fantastic team of analysts based in our office out in Mumbai. Popat sat…
Tom Brockbank Consultant Joined GPI in May 2018 This weeks Employee Spotlight focuses on Tom Brockbank. Tom is a part of the core consultancy team based in our London office, whom help to guide our clients consulting requests on a daily basis….
Fertile ground for cross-border cooperation Even with pan-European EMA approval, pricing is still a country-level issue, with national governments, regional or local stakeholders and pharmaceutical companies being responsible for engaging in price formalities such as negotiations on a bilateral basis. But the landscape…
Biosimilar launches of antineoplastic monoclonal antibodies represent a milestone in oncological care but also a new chapter in the application of biosimilars; introducing more prescribers, payers and stakeholders to the biological copies. Rituximab biosimilars came to the European market in 2017, while trastuzumab…
Legal questions around the “Mischpreis” pricing approach are still hanging over sickness funds and manufacturers in Germany. The current price setting methodology as part of AMNOG negotiations take average weighted prices and considers the value and price potential across all indications and patient…
Brexit: in or out? If you have lived in the UK for the past year, or anywhere else in the world for that matter, you are probably very familiar with the term. As one of the biggest political decisions of the 21st century,…
